The ISYNA1 Knockout HeLa Polyclonal Cells are a CRISPR/Cas9-edited polyclonal population of HeLa cells with targeted disruption of the ISYNA1 gene. This product provides a loss-of-function model to investigate de novo myo-inositol biosynthesis and downstream phosphoinositide signaling. The polyclonal format retains a heterogeneous gene-edited population, suitable for studying gene function without clonal selection artifacts. As a research tool, these cells enable dissection of ISYNA1-dependent pathways in a well-characterized cancer cell background.
HeLa cells are an immortalized human cervical adenocarcinoma epithelial line, positive for human papillomavirus 18 (HPV18) and exhibiting an aneuploid karyotype. They serve as a cornerstone model in cancer biology, signal transduction research, and drug development. The HPV-derived E6 and E7 oncoproteins inactivate p53 and retinoblastoma (Rb) tumor suppressors, driving uncontrolled proliferation and altering metabolic networks. This cellular context is highly relevant for examining how ISYNA1-mediated inositol metabolism intersects with HPV-induced transformation and cancer cell signaling.
ISYNA1 encodes myo-inositol-1-phosphate synthase, which catalyzes the conversion of glucose-6-phosphate to myo-inositol 1-phosphate??the rate-limiting step in de novo myo-inositol synthesis. The enzyme is regulated by insulin signaling and hypoxia-inducible factor 1-alpha (HIF-1??), linking its activity to glucose availability and cellular stress. Myo-inositol 1-phosphate is subsequently dephosphorylated by inositol monophosphatases (IMPA1/IMPA2) to free myo-inositol, a substrate for phosphatidylinositol synthase (PIS) to produce phosphatidylinositol (PI). PI is phosphorylated to phosphatidylinositol 4,5-bisphosphate (PIP2), which is cleaved by phospholipase C (PLC) into inositol 1,4,5-trisphosphate (IP3) and diacylglycerol (DAG), activating calcium signaling and protein kinase C (PKC). PI can also be phosphorylated by PI3K to generate phosphatidylinositol 3,4,5-trisphosphate (PIP3), leading to AKT activation. Thus, ISYNA1 is a critical upstream node controlling the phosphoinositide pool and multiple downstream effectors.
In the HeLa background, ISYNA1 knockout disrupts myo-inositol production, depleting phosphoinositides and attenuating PI3K/AKT and PKC signal transduction. Given that AKT signaling is frequently hyperactivated in cervical cancers, this model permits direct interrogation of the metabolic dependency of HPV-positive cancer cells on endogenous inositol synthesis. Loss of ISYNA1 may impair cell proliferation, migration, and survival, while also modulating sensitivity to therapeutic agents such as PI3K inhibitors or lithium??an inhibitor of inositol monophosphatase. This makes the knockout population a valuable system for linking metabolic rewiring to oncogenic signaling in cervical adenocarcinoma.
Typical applications include investigating myo-inositol biosynthesis in cervical cancer, dissecting phosphoinositide-mediated signaling networks, and performing drug screening for inhibitors of inositol metabolism. Researchers can employ quantitative LC-MS for myo-inositol measurement, Western blotting for phospho-AKT and PKC substrates, immunofluorescence to visualize PIP2 distribution, and migration assays to assess functional consequences. Drug sensitivity profiling with compounds such as lithium or PI3K inhibitors can reveal therapeutic vulnerabilities. These polyclonal knockout cells thus support a broad range of cell biology, cancer, and metabolic signaling studies. For further information, please contact Ascent Research.
